Please assess the completion status of the following clinical trial:

Trial Title: IU Health Krannert Personalized Medicine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ischemic heart disease, who are prescribed dual antiplatelet therapy after percutaneous coronary intervention (PCI). Enrollment has to occur during index hospitalization or during outpatient visit for cath lab procedure.~Exclusion Criteria:~* Pregnant or breastfeeding.~* Unwilling or unable, in the opinion of the investigator, to comply with instructions on prescribed medicines.~* Prior known allergy or intolerance to clopidogrel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pharmacogenetic Results Available to Provider (Type: ACTIVE_COMPARATOR): Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
- Control Arm (Type: NO_INTERVENTION): No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.

Based on this trial design, predict the completion outcome and termination type (if applicable).